Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

Uncover the truth about GLP-1 weight loss drugs like Ozempic and Mounjaro. Learn how they work, who benefits most, potential risks, and why experts say they can be game-changing tools for fighting ...

Mounjaro, one of the UK’s most popular weight-loss jabs, is set to become more expensive for private patients after Eli Lilly ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight, potentially transforming diabetes and obesity treatment.

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

The injection was initially licensed to treat type 2 diabetes, but is now also prescribed to help with weight loss ...

By Brooke Hudspeth, Pharm.D. University of Kentucky You’ve likely heard about glucagon-like peptide-1 agonists – usually ...

The pharmaceutical company said the move is intended to "address pricing inconsistencies compared with other developed ...

WEIGHT loss jabs have been hailed as revolutionary for tackling the obesity crisis for their significant results and potential to prevent obesity-related diseases. But stopping the weight loss ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

A supplement succeeds when it fits your life. PhenQ is meant to be simple: one capsule with breakfast, one with lunch.

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.